Skip to main content

Table 4 Cost-effectiveness analysis results over a life-time horizon

From: Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain

Indicator Costs LYs QALYs
Treatment AZA comparator AZA comparator AZA comparator
AZA vs. BSC 107,168 35,090 4.05 1.88 3.06 1.24
ICER    €33,111/LY gained € 39,610/QALY gained
AZA vs. LDC 115,537 53,184 4.45 2.06 3.39 1.36
ICER    €25,953/LY gained €30,531/QALY gained
AZA vs. SDC 106,422 59,725 3.96 1.49 2.94 0.98
ICER    €18,884/LY gained €23,804/QALY gained
AZA vs. CCR* 108,605 43,170 4.11 1.85 3.11 1.22
ICER    €28,891/LY gained €34,673/QALY gained
  1. Abbreviations: AZA = Azacitidine; BSC = best supportive care; LDC = low dose chemotherapy; SDC = standard dose chemotherapy; CCR = conventional care regimen; QALY = Quality adjusted life year; LY = Life year.
  2. * Data were pooled corresponding to the number of patients in the AZA-001 study for each treatment.